Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Die MorphoSys AG (FSE: MOR; NASDAQ: MOR) hat heute bekanntgegeben, dass im Rahmen eines mündlichen Vortrags neue Wirksam…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
The X-Smart Pro+ endodontic motor with integrated Apex Locator was recently honored with the international iF Design Awa…
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor t…